[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100159133":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":40,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":11,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Laboratoires Thea","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"T1210","EXPERIMENTAL",null,[13],"Drug: T1210",{"label":15,"type":16,"description":11,"interventionNames":17},"Olopatadine hydrochloride","ACTIVE_COMPARATOR",[18],"Drug: Olopatadine hydrochloride",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","2 drops T1210 once a day",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"2 drops once a day Olopatadine",[15],[28],{"facility":29,"status":11,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":11},"Pierre Huguet","Clermont-Ferrand","63000","France","FR",{"type":35,"coordinates":36},"Point",[37,38],3.08682,45.77969,{"lat":38,"lon":37},{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100159133","phase-2-comparison-of-the-efficacy-and-tolerability-of-t1210-and-olopatadine-hydrochloride-01-in-the-treatment-of-seasonal-allergic-conjunctivitis-100159133",false,"NCT01344083","Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis","Inclusion Criteria:\n\n* Written informed consent\n* Conjunctivitis allergic conjunctivitis\n\nExclusion Criteria:\n\n* Severe ocular allergy\n* Vernal keratoconjunctivitis","ALL","18 Years","80 Years",{"count":52,"type":53},60,"ESTIMATED","INTERVENTIONAL",[56],"PHASE2","The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.",[59],"Seasonal Allergic Conjunctivitis","COMPLETED","2012-04-11",{"date":63,"type":53},"2012-04-12",{"date":65,"type":11},"2011-04",{"date":67,"type":68},"2012-02","ACTUAL",{"name":5,"class":6},1]